Interleukin-1 receptor antagonist (IL-1Ra) and IL-1Ra producing mesenchymal stem cells as modulators of diabetogenesis

References

• Eizirik DL, Mandrup-Poulsen T. A choice of death. The signal transduction of immune-mediated β-cell apoptosis. Diabetologia. 2001; 44:2115–2133.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA. Pathogenesis of type 2 diabetes: Metabolic and molecular implications for identifying diabetes genes. Diabet Rev. 1997; 5:177–269.
   Google Scholar
• Hani EH, Stoffers DA, Chèvre JC, Durand E, Stanojevic V, Dina C, Habener JF, Froguel P. Defective mutations in the insulin promoter factor-1 (IPF-1) gene in late-onset type 2 diabetes mellitus. J Clin Invest. 1999; 104:R41–R48.
   PubMed Web of Science ®Google Scholar
• Rother K. Diabetes treatment-bridging the divide. N Engl J Med. 2007; 356:1499–1501.
   PubMed Web of Science ®Google Scholar
• Ortiz LA, Dutreil M, Fattman C, Pandey AC, Torres G, Go K, Phinney DG. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci USA. 2007; 104:11002–11007.
   PubMed Web of Science ®Google Scholar
• Seckinger P, Lowenthal JW, Williamson K, Dayer JM, MacDonald HR. A urine inhibitor of interleukin 1 activity that blocks ligand binding. J Immunol. 1987; 139:1546–1549.
   PubMed Web of Science ®Google Scholar
• Lukic ML, Stosic-Grujicic S, Ostojic N, Chan WL, Liew FY. Inhibition of nitric oxide generation affects the induction of diabetes by streptozotocin. Biochem Biophys Res Commun. 1991; 178:913–920.
   PubMed Web of Science ®Google Scholar
• Dinarello CA. The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1. N Engl J Med. 2000; 343:732–734.
   PubMed Web of Science ®Google Scholar
• Roux-Lombard P, Modoux C, Dayer JM. Production of interleukin-1 (IL-1) and a specific IL-1 inhibitor during human monocyte–macrophage differentiation: Influence of GM-CSF. Cytokine. 1989; 1:45–51.
   PubMedGoogle Scholar
• Kristensen M, Deleuran B, Eedy DJ, Feldmann M, Breathnac SN, Brennan FM. Distribution of interleukin 1 receptor antagonist protein (IRAP), interleukin 1 receptor, and interleukin 1 alpha in normal and psoriatic skin. Decreased expression of IRAP in psoriatic lesional epidermis. Br J Dermatol. 1992; 127:305–311.
   PubMedGoogle Scholar
• Chan LS, Hammerberg C, Kang K, Sabb P, Tavakkol A, Cooper KD. Human dermal fibroblast interleukin-1 receptor antagonist (IL-1ra) and interleukin-1 beta (IL-1 beta) mRNA and protein are co-stimulated by phorbol ester: Implication for a homeostatic mechanism. J Invest Dermatol. 1992; 99:315–322.
   PubMed Web of Science ®Google Scholar
• Dewberry R, Holden H, Crossman D, Francis S. Interleukin-1 receptor antagonist expression in human endothelial cells and atherosclerosis. Arterioscler Thromb Vasc Biol. 2000; 20:2394–2400.
   PubMed Web of Science ®Google Scholar
• Juge-Aubry CE, Somm E, Chicheportiche R, Burger D, Pernin A, Cuenod-Pittet B, Quinodoz P, Giusti V, Dayer JM, Meier CA. Regulatory effects of interleukin (IL)-1, interferon-beta, and IL-4 on the production of IL-1 receptor antagonist by human adipose tissue. J Clin Endocrinol Metab. 2004; 89:2652–2658.
   Google Scholar
• Perrier S, Kherratia B, Deschaumes C, Ughetto S, Kemeny JL, Baudet-Pommel M, Sauvezie B. IL-1ra and IL-1 production in human oral mucosal epithelial cells in culture: Differential modulation by TGF-beta1 and IL-4. Clin Exp Immunol. 2002; 127:53–59.
   Google Scholar
• Daig R, Rogler G, Aschenbrenner E, Vogl D, Falk W, Gross V, Scholmerich J, Andus T. Human intestinal epithelial cells secrete interleukin-1 receptor antagonist and interleukin-8 but not interleukin-1 or interleukin-6. Gut. 2000; 46:350–358.
   PubMed Web of Science ®Google Scholar
• Gabay C, Smith MF, Eidlen D, Arend WP. Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein. J Clin Invest. 1997; 99:2930–2940.
   PubMed Web of Science ®Google Scholar
• Netea MG, Hancu N, Blok WL, Grigorescu-Sido P, Popa L, Popa V, van der Meer JW. Interleukin 1 beta, tumour necrosis factor-alpha and interleukin 1 receptor antagonist in newly diagnosed insulin-dependent diabetes mellitus: Comparison to long-standing diabetes and healthy individuals. Cytokine. 19974: 284–287.
   Google Scholar
• Mandrup-Poulsen T, Bendtzen K, Nerup J, Dinarello CA, Svenson M, Neilsenet JH. Affinity purified human interleukin-1 is cytotoxic to isolated islets of Langerhans. Diabetologia. 1986; 29:63–67.
   PubMed Web of Science ®Google Scholar
• Wilson CA, Jacobs C, Baker P, Baskin DG, Dower S, Lernmark A, Toivola B, Vertrees S, Wilson D. Interleukin-1 beta modulation of spontaneous autoimmune diabetes and thyroiditis in the BB rat. J Immunol. 1990; 144:3784–3788.
   PubMed Web of Science ®Google Scholar
• Wogensen LD, Reimers J, Nerup J, Kolb-Bachofen V, Kroncke KD, Almdal T, Mandrup-Poulsen T. Repetitive in vivo treatment with human recombinant interleukin-1 beta modifies beta cell function in normal rats. Diabetologia. 1992; 35:331–339.
   Google Scholar
• Eizirik DL, Tracey DE, Bendtzen K, Sandler S. An interleukin-1 receptor antagonist protein protects insulin-producing beta cells against suppressive effects of interleukin-1 beta. Diabetologia. 1991; 34:445–448.
   PubMed Web of Science ®Google Scholar
• Stosić-Grujicić S, Lukić M, Ostajić N. Interleukin 1 receptor antagonists prevent the induction of experimental insulin-dependent autoimmune diabetes. Srp Arh Celok Lek. 1994; 122 Suppl. l: 11–12.
   Google Scholar
• Stosić-Grujicić S, Lukić ML. Glucocorticoid-induced keratinocyte-derived interleukin-1 receptor antogonist. Immunology. 1992; 75:292–298.
   Google Scholar
• Pfleger C, Mortensen HB, Hansen L, Herder C, Roep BO, Hoey H, Aanstoot HJ, Kocova M, Schloot NC. Association of IL-1ra and adiponectin with C-peptide and remission in patients with type 1 diabetes. Diabetes. 2008; 57:929–937.
   PubMed Web of Science ®Google Scholar
• Juge-Aubry CE, Somm E, Giusti V, Pernin A, Chicheportiche R, Verdumo C, Rohner-Jeanrenaud F, Burger D, Dayer JM, Meier CA. Adipose tissue is a major source of interleukin-1 receptor antagonist: Upregulation in obesity and inflammation. Diabetes. 2003; 52:1104–1110.
   PubMed Web of Science ®Google Scholar
• Mandrup-Poulsen T, Zumsteg U, Reimers J, Pociot F, Mørch L, Helqvist S, Dinarello CA, Nerup J. Involvement of interleukin 1 and interleukin 1 antagonist in pancreatic beta-cell destruction in insulin-dependent diabetes mellitus. Cytokine. 1993; 5:185–191.
   PubMed Web of Science ®Google Scholar
• Sandberg JO, Andersson A, Eizirik DL, Sandlers S. Interleukin-1 receptor antagonist prevents low dose streptozotocin induced diabetes in mice. Biochem Biophys Res Commun. 1994; 202:543–548.
   PubMed Web of Science ®Google Scholar
• Eizirik DL. Interleukin-1 beta induces an early decrease in insulin release, (pro) insulin biosynthesis and insulin mRNA in mouse pancreatic islets by a mechanism dependent on gene transcription and protein synthesis. Autoimmunity. 1991; 10:107–113.
   PubMed Web of Science ®Google Scholar
• Sandler S, Andersson A, Hellerstrom C. Inhibitory effects of interleukin 1 on insulin secretion, insulin biosynthesis, and oxidative metabolism of isolated rat pancreatic islets. Endocrinology. 1987; 121:1424–1431.
   PubMed Web of Science ®Google Scholar
• Giannoukakis N, Rudert WA, Trucco M, Robbins PD. Protection of human islets from the effects of interleukin-1beta by adenoviral gene transfer of an IkappaB repressor. J Biol Chem. 2000; 275:36509–36513.
   PubMed Web of Science ®Google Scholar
• Téllez N, Montolio M, Biarnés M, Castaño E, Soler J, Montanya E. Adenoviral overexpression of interleukin-1 receptor antagonist protein increases beta-cell replication in rat pancreatic islets. Gene Ther. 2005; 12:120–128.
   PubMed Web of Science ®Google Scholar
• Giannoukakis N, Rudert WA, Ghivizzani SC, Gambotto A, Ricordi C, Trucco M, Robbins PD. Adenoviral gene transfer of the interleukin-1 receptor antagonist protein to human islets prevents IL-1b–induced b-cell impairment and activation of islet cell apoptosis in vitro. Diabetes. 1999; 48:1730–1736.
   PubMed Web of Science ®Google Scholar
• Frank KM, Hogarth DK, Miller JL, Mandal S, Mease PJ, Samulski RJ, Weisgerber GA, Hart J. Investigation of the cause of death in a gene-therapy trial. N Engl J Med. 2009; 361 2: 161–169.
   Google Scholar
• Donath MY, Mandrup-Poulsen T. The use of interleukin-1-receptor antagonists in the treatment of diabetes mellitus. Nat Clin Pract Endocrinol Metab. 2008; 4:240–241.
   Google Scholar
• Donath MY, Størling J, Berchtold LA, Billestrup N, Mandrup-Poulsen T. Cytokines and beta-cell biology: From concept to clinical translation. Endocr Rev. 2008; 29:334–350.
   PubMed Web of Science ®Google Scholar
• Maedler K, Sergeev P, Ris F, Oberholzer J, Joller-Jemelka HI, Spinas GA, Kaiser N, Halban PA, Donath MY. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest. 2002; 110:851–860.
   PubMed Web of Science ®Google Scholar
• Ehses JA, Perren A, Eppler E, Ribaux P, Pospisilik JA, Maor-Cahn R, Gueripel X, Ellingsgaard H, Schneider MK, Biollaz G, Fontana A, Reinecke M, Homo-Delarche F, Donath MY. Increased number of islet-associated macrophages in type 2 diabetes. Diabetes. 2007; 56:2356–2370.
   PubMed Web of Science ®Google Scholar
• Donath MY, Schumann DM, Faulenbach M, Ellingsgaard H, Perren A, Ehses JA. Islet inflammation in type 2 diabetes: From metabolic stress to therapy. Diabetes Care. 2008; 31 Suppl. 2: 161–164.
   PubMed Web of Science ®Google Scholar
• Böni-Schnetzler M, Thorne J, Parnaud G, Marselli L, Ehses JA, Kerr-Conte J, Pattou F, Halban PA, Weir GC, Donath MY. Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta-cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation. J Clin Endocrinol Metab. 2008; 93 10: 4065–4074.
   Google Scholar
• Sauter NS, Schulthess FT, Galasso R, Castellani LW, Maedler K. The antiinflammatory cytokine interleukin-1 receptor antagonist protects from high-fat diet-induced hyperglycemia. Endocrinology. 2008; 149:2208–2218.
   PubMed Web of Science ®Google Scholar
• Larsen CM, Faulenbach M, Vaag A, Vølund A, Ehses JA, Seifert B, Mandrup-Poulsen T, Donath MY. Interleukin-1–receptor antagonist in type 2 diabetes mellitus. N Engl J Med. 2007; 356:1517–1526.
   PubMed Web of Science ®Google Scholar
• Dinarello CA. The many worlds of reducing interleukin-1. Arthr Rheum. 2005; 52:1960–1967.
   PubMed Web of Science ®Google Scholar
• Porada CD, Zanjani ED, Almeida-Porad G. Adult mesenchymal stem cells: A pluripotent population with multiple applications. Curr Stem Cell Res Ther. 2006; 1:365–369.
   PubMedGoogle Scholar
• Tyndall A, Walker UA, Cope A, Dazzi F, De Bari C, Fibbe W, Guiducci S, Jones S, Jorgensen C, Pennesi G, Pistoia V, Pitzalis C, Uccelli A, Wulffraat N, Feldmann M. Immunomodulatory properties of mesenchymal stem cells: A review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 October 2005. Arthritis Res Ther. 2007; 9:301.
   PubMed Web of Science ®Google Scholar
• Gnecchi M, Melo LG. Bone marrow-derived mesenchymal stem cells: Isolation, expansion, characterization, viral transduction, and production of conditioned medium. Methods Mol Biol. 2009; 482:281–294.
   PubMedGoogle Scholar
• Delorme B, Charbord P. Culture and characterization of human bone marrow mesenchymal stem cells. Methods Mol Med. 2007; 140:67–81.
   PubMedGoogle Scholar
• Yamamoto N, Akamatsu H, Hasegawa S, Yamada T, Nakata S, Ohkuma M, Miyachi E, Marunouchi T, Matsunaga K. Isolation of multipotent stem cells from mouse adipose tissue. J Dermatol Sci. 2007; 48:43–52.
   PubMed Web of Science ®Google Scholar
• Lu LL, Liu YJ, Yang SG, Zhao QJ, Wang X, Gong W, Han ZB, Xu ZS, Lu YX, Liu D, Chen ZZ, Han ZC. Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. Haematologica. 2006; 91:1017–1026.
   PubMed Web of Science ®Google Scholar
• Bieback K, Klüter H. Mesenchymal stromal cells from umbilical cord blood. Curr Stem Cell Res Ther. 2007; 2:310–323.
   Google Scholar
• da Silva Meirelles L, Chagastelles PC, Nardi NB. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci. 2006; 119:2204–2213.
   PubMed Web of Science ®Google Scholar
• Short BJ, Brouard N, Simmons PJ. Prospective isolation of mesenchymal stem cells from mouse compact bone. Methods Mol Biol. 2009; 482:259–268.
   PubMedGoogle Scholar
• Polisetty N, Fatima A, Madhira SL, Sangwan VS, Vemuganti GK. Mesenchymal cells from limbal stroma of human eye. Mol Vis. 2008; 14:431–432.
   PubMed Web of Science ®Google Scholar
• Chamberlain G, Fox J, Ashton B, Middleton J. Concise review: Mesenchymal stem cells: Their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells. 2007; 25:2739–2749.
   PubMed Web of Science ®Google Scholar
• Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science. 1997; 276:71–74.
   PubMed Web of Science ®Google Scholar
• Abdi R, Fiorina P, Adra CN, Atkinson M, Sayegh MH. Immunomodulation by mesenchymal stem cells: A potential therapeutic strategy for type 1 diabetes. Diabetes. 2008; 57:1759–1767.
   PubMed Web of Science ®Google Scholar
• Augello A, Tasso R, Negrini SM, Amateis A, Indiveri F, Cancedda R, Pennesi G. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol. 2005; 35:1482–1490.
   PubMed Web of Science ®Google Scholar
• Ryan JM, Barry FP, Murphy JM, Mahon BP. Mesenchymal stem cells avoid allogeneic rejection. J Inflamm (Lond). 2005; 2:8.
   PubMedGoogle Scholar
• Nauta AJ, Kruisselbrink AB, Lurvink E, Willemze R, Fibbe WE. Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. J Immunol. 2006; 177:2080–2087.
   PubMed Web of Science ®Google Scholar
• Mahnke K, Schmitt E, Bonifaz L, Enk AH, Jonuleit H. Immature, but not inactive: The tolerogenic function of immature dendritic cells. Immunol Cell Biol. 2002; 80:477–483.
   PubMed Web of Science ®Google Scholar
• Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood. 2007; 110:3499–3506.
   PubMed Web of Science ®Google Scholar
• Selmani Z, Naji A, Zidi I, Favier B, Gaiffe E, Obert L, Borg C, Saas P, Tiberghien P, Rouas-Freiss N, Carosella ED, Deschaseaux F. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells. 2008; 26:212–222.
   PubMed Web of Science ®Google Scholar
• Deng W, Han Q, Liao L, You S, Deng H, Zhao RC. Effects of allogeneic bone marrow-derived mesenchymal stem cells on T- and B-lymphocytes from BXSB mice. DNA Cell Biol. 2005; 24:458–463.
   PubMed Web of Science ®Google Scholar
• Dayer JM, Burger D. Interleukin-1, tumor necrosis factor and their specific inhibitors. Eur Cytokine Netw. 1994; 5:563–571.
   PubMed Web of Science ®Google Scholar
• Cavaillon JM. Contribution of cytokines to inflammatory mechanisms. Pathol Biol (Paris). 1993; 41:799–811.
   Google Scholar
• Cavaillon JM, Haeffner-Cavaillon N. Cytokines and inflammation. Rev Prat. 1993; 43:547–552.
   PubMedGoogle Scholar
• Cavaillon JM. Cytokines in inflammation. C R Seances Soc Biol Fil. 1995; 189:531–544.
   Google Scholar
• Lee RH, Seo MJ, Reger RL, Spees JL, Pulin AA, Olson SD, Prockop DJ. Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. Proc Natl Acad Sci USA. 2006; 103:17438–17443.
   PubMed Web of Science ®Google Scholar
• Ezquer FE, Ezquer ME, Parrau DB, Carpio D, Yañez AJ, Conget PA. Systemic administration of multipotent mesenchymal stromal cells reverts hyperglycemia and prevents nephropathy in type 1 diabetic mice. Biol Blood Marrow Transplant. 2008; 14:631–640.
   PubMed Web of Science ®Google Scholar
• Abdel Aziz MT, El-Asmar MF, Haidara M, Atta HM, Roshdy NK, Rashed LA, Sabry D, Youssef MA, Abdel Aziz AT, Moustafa M. Effect of bone marrow-derived mesenchymal stem cells on cardiovascular complications in diabetic rats. Med Sci Monit. 2008; 14:BR249–BR255.
   Google Scholar
• Kwon DS, Gao X, Liu YB, Dulchavsky DS, Danyluk AL, Bansal M, Chopp M, McIntosh K, Arbab AS, Dulchavsky SA, Gautam SC. Treatment with bone marrow-derived stromal cells accelerates wound healing in diabetic rats. Int Wound J. 2008; 5:453–463.
   PubMed Web of Science ®Google Scholar
• Shibata T, Naruse K, Kamiya H, Kozakae M, Kondo M, Yasuda Y, Nakamura N, Ota K, Tosaki T, Matsuki T, Nakashima E, Hamada Y, Oiso Y, Nakamura J. Transplantation of bone marrow-derived mesenchymal stem cells improves diabetic polyneuropathy in rats. Diabetes. 2008; 57:3099–3107.
   PubMed Web of Science ®Google Scholar
• English K, Ryan JM, Tobin L, Murphy MJ, Barry FP, Mahon BP. Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(high)forkhead box P3+ regulatory T cells. Clin Exp Immunol. 2009; 156 1: 149–160.
   PubMed Web of Science ®Google Scholar
• Tolar J, Nauta AJ, Osborn MJ, Panoskaltsis Mortari A, McElmurry RT, Bell S, Xia L, Zhou N, Riddle M, Schroeder TM, Westendorf JJ, McIvor RS, Hogendoorn PC, Szuhai K, Oseth L, Hirsch B, Yant SR, Kay MA, Peister A, Prockop DJ, Fibbe WE, Blazar BR. Sarcoma derived from cultured mesenchymal stem cells. Stem Cells. 2007; 25:371–379.
   PubMed Web of Science ®Google Scholar
• Breitbach M, Bostani T, Roell W, Xia Y, Dewald O, Nygren JM, Fries JW, Tiemann K, Bohlen H, Hescheler J, Welz A, Bloch W, Jacobsen SE, Fleischmann BK. Potential risks of bone marrow cell transplantation into infarcted hearts. Blood. 2007; 110:1362–1369.
   PubMed Web of Science ®Google Scholar
• Atsma DE, Fibbe WE, Rabelink TJ. Opportunities and challenges for mesenchymal stem cell-mediated heart repair. Curr Opin Lipidol. 2007; 18:645–649.
   Google Scholar